Cited 0 times in
Intravenous 5-Fluorouracil Versus Oral Doxifluridine as Preoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Prospective Randomized Trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 노재경 | - |
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2016-02-19T11:14:29Z | - |
dc.date.available | 2016-02-19T11:14:29Z | - |
dc.date.issued | 2001 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/142709 | - |
dc.description.abstract | BACKGROUND: Preoperative radiation treatment with concomitant intravenous infusion of 5-fluorouracil (5-FU) is known to be effective in shrinking and downstaging of tumors. However, chemotherapy has often been limited by its toxicity and poor patient compliance. Oral 5-FU is known to have several advantages over conventional intravenous 5-FU infusion such as lower toxicity and higher quality of life without compromising the efficacy of the treatment. The aim of this study was to compare intravenous 5-FU with oral doxifluridine with respect to tumor response, toxicity and quality of life. METHODS: Twenty-eight patients with rectal cancer, staged as over T3N1 or T4 by transrectal ultrasonography between July 1997 and December 1998, were included in this study. Intravenous 5-FU (450 mg/m2) and leucovorin (20 mg/m2) were given for five consecutive days during the first and fifth weeks of radiation therapy (50.4 Gy) (n = 14). Oral doxifluridine (700 mg/m2/day) and leucovorin (20 mg/m2) were given daily during radiation treatment (n = 14). Quality of life was scored according to 22 activity items (good, >77; fair, >58; poor, <57). Surgical resection was performed 4 weeks after completion of concurrent chemoradiation treatment. Tumor response was classified into CR (complete remission), PR (partial response; 50% diminution of tumor volume or downstaging ) and NR (no response). RESULTS: Tumor response was CR 3/14 (21.4%), PR 7/14 (50%) and NR 4/14 (28.6%) in the IV arm versus CR 2/14 (14.2%), PR 6/14 (42.9%) and NR 6/14 (42.9%) in the Oral arm (p = 0.16, 0.23, 0.24), respectively. The quality of life was poor (36.4% versus 33.3%), fair and good (63.6% versus 66.7%) between the IV arm and Oral arm, respectively. Gastrointestinal toxicity was 2/14 (14.3%) in the IV arm versus 5/14 (35.7%) in the Oral arm, respectively. Stomatitis was only observed in the IV arm (1/14, 7.1%). Hematological toxicity was 3/14 (21.4%) in the IV arm versus 4/14 (28.5%) in the Oral arm, respectively. Systemic recurrence during the follow-up periods were 1/14 (7.1%) in the IV arm and 2/14 (14.3%) in the Oral arm, respectively (p = 0.307). One local recurrence was observed in the Oral arm. CONCLUSION: Even though the results were not entirely reliable owing to the small number of patients enrolled, oral doxifluridine-based chemotherapy as preoperative chemoradiation for advanced rectal cancer did not show any significant advantages over intravenous infusio | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 25~29 | - |
dc.relation.isPartOf | JAPANESE JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Administration, Oral | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/therapeutic use* | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Floxuridine/therapeutic use* | - |
dc.subject.MESH | Fluorouracil/therapeutic use* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infusions, Intravenous | - |
dc.subject.MESH | Leucovorin/administration & dosage | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Quality of Life | - |
dc.subject.MESH | Rectal Neoplasms/drug therapy | - |
dc.subject.MESH | Rectal Neoplasms/radiotherapy | - |
dc.subject.MESH | Rectal Neoplasms/surgery | - |
dc.subject.MESH | Rectal Neoplasms/therapy* | - |
dc.title | Intravenous 5-Fluorouracil Versus Oral Doxifluridine as Preoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Prospective Randomized Trials | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Nam Kyu Kim | - |
dc.contributor.googleauthor | Jin Sik Min | - |
dc.contributor.googleauthor | Jea Kun Park | - |
dc.contributor.googleauthor | Seong Hyun Yun | - |
dc.contributor.googleauthor | Jin Sil Sung | - |
dc.contributor.googleauthor | Hyun Chul Jung | - |
dc.contributor.googleauthor | Jae Kyung Roh | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01290 | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J01207 | - |
dc.identifier.eissn | 1465-3621 | - |
dc.identifier.pmid | 11256837 | - |
dc.subject.keyword | rectal cancer | - |
dc.subject.keyword | preoperative chemoradiation | - |
dc.subject.keyword | intravenous 5-fluorouracil | - |
dc.subject.keyword | oral doxifluridine | - |
dc.contributor.alternativeName | Roh, Jae Kyung | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Roh, Jae Kyung | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 31 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 25 | - |
dc.citation.endPage | 29 | - |
dc.identifier.bibliographicCitation | JAPANESE JOURNAL OF CLINICAL ONCOLOGY, Vol.31(1) : 25-29, 2001 | - |
dc.identifier.rimsid | 29784 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.